[1] |
Zhan Y, Dahabieh MS, Rajakumar A, et al. The role of eIF4E in response and acquired resistance to vemurafenib in melanoma[J]. J Invest Dermatol, 2015, 135(5): 1368⁃1376. DOI: 10.1038/jid.2015.11.
|
[2] |
Groner B, Weiss A. Targeting survivin in cancer: novel drug development approaches[J]. BioDrugs, 2014, 28(1): 27⁃39. DOI: 10.1007/s40259⁃013⁃0058⁃x.
|
[3] |
Mamatha B, Nathaniel R, Laura H, et al. Targeting the translation machinery in cancer[J]. Nat Rev Drug Discov, 2015, 14(4): 261⁃78. DOI: 10.1038/nrd4505.
|
[4] |
Pettersson F, Del Rincon SV, Jr MW. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond[J]. Expert Opin Ther Targets, 2014, 18(9): 1035⁃1048. DOI: 10.1517/14728222.2014.937426.
|
[5] |
Laplante M, Sabatini D. mTOR signaling in growth control and disease[J]. Cell, 2012, 149(2): 274⁃293. DOI: 10.1016/j.cell.2012.03.017.
|
[6] |
Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing[J]. Nat Rev Mol Cell Bio, 2011, 12(1): 21⁃35. DOI: 10.1038/nrm3025.
|
[7] |
Dowling RJ, Topisirovic I, Alain T, et al. mTORC1⁃mediated cell proliferation, but not cell growth, controlled by the 4E⁃BPs[J]. Science, 2010, 328(5982): 1172⁃1176. DOI: 10.1126/science.1187532.
|
[8] |
Shin S, Wolgamott L, Tcherkezian J, et al. Glycogen synthase kinase⁃3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E⁃binding protein 1[J]. Oncogene, 2014, 33(13): 1690⁃1699. DOI: 10.1038/onc.2013.113.
|
[9] |
Khosravi S, Ardekani GS, Martinka M, et al. eIF4E, an adverse prognostic marker of melanoma patient survival, increases melanoma cell invasion[J]. Cancer Res, 2014, 74(19): 3145. DOI: 10.1158/1538⁃7445.AM2014⁃3145.
|
[10] |
Salehi Z, Mashayekhi F, Shahosseini F. Significance of eIF4E in skin squamous cell carcinoma[J]. Cell Bio Int, 2007, 31(11): 1400⁃1404. DOI: 10.1016/j.cellbi.2007.06.006.
|
[11] |
Jiang CC, Croft A, Tseng HY, et al. Repression of microRNA⁃768⁃3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma[J]. Oncogene, 2013, 33(20): 2577⁃2588. DOI: 10.1038/onc.2013.237.
|
[12] |
Pelletier J, Graff J, Ruggero D, et al. Targeting the eIF4F transla⁃tion initiation complex: a critical nexus for cancer development[J]. Cancer research, 2015, 75(2): 250⁃263. DOI: 10.1158/0008⁃5472.CAN⁃14⁃2789.
|
[13] |
Groner B, Weiss A. Targeting survivin in cancer: novel drug development approaches[J]. BioDrugs, 2014, 28(1): 27⁃39. DOI: 10.1007/s40259⁃013⁃0058⁃x.
|